These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 37440421)

  • 1. Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials.
    Doppenberg D; van Dam JL; Han Y; Bonsing BA; Busch OR; Festen S; van der Harst E; de Hingh IH; Homs MYV; Kwon W; Lee M; Lips DJ; de Meijer VE; Molenaar IQ; Nuyttens JJ; Patijn GA; van Roessel S; van der Schelling GP; Suker M; Versteijne E; de Vos-Geelen J; Wilmink JW; van Eijck CHJ; van Tienhoven G; Jang JY; Besselink MG; Groot Koerkamp B;
    Br J Surg; 2023 Sep; 110(10):1374-1380. PubMed ID: 37440421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comment on: Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials.
    Underwood PW; Cloyd JM
    Br J Surg; 2024 Apr; 111(4):. PubMed ID: 38568860
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of neoadjuvant treatment in resectable pancreatic cancer according to vessel invasion and increase of CA19-9 levels.
    Kim HS; Lee M; Han Y; Kang JS; Kang YH; Sohn HJ; Kwon W; Lee DH; Jang JY
    J Hepatobiliary Pancreat Sci; 2023 Jul; 30(7):924-934. PubMed ID: 36652346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.
    Versteijne E; van Dam JL; Suker M; Janssen QP; Groothuis K; Akkermans-Vogelaar JM; Besselink MG; Bonsing BA; Buijsen J; Busch OR; Creemers GM; van Dam RM; Eskens FALM; Festen S; de Groot JWB; Groot Koerkamp B; de Hingh IH; Homs MYV; van Hooft JE; Kerver ED; Luelmo SAC; Neelis KJ; Nuyttens J; Paardekooper GMRM; Patijn GA; van der Sangen MJC; de Vos-Geelen J; Wilmink JW; Zwinderman AH; Punt CJ; van Tienhoven G; van Eijck CHJ;
    J Clin Oncol; 2022 Apr; 40(11):1220-1230. PubMed ID: 35084987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of the serum CA19-9 level in "biological borderline resectability" and "biological downstaging" in the setting of preoperative chemoradiation therapy for pancreatic cancer.
    Takahashi H; Yamada D; Asukai K; Wada H; Hasegawa S; Hara H; Shinno N; Ushigome H; Haraguchi N; Sugimura K; Yamamoto K; Nishimura J; Yasui M; Omori T; Miyata H; Ohue M; Yano M; Sakon M; Ishikawa O
    Pancreatology; 2020 Jul; 20(5):919-928. PubMed ID: 32563596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer: reconstructed patient-level meta-analysis of randomized clinical trials.
    Aliseda D; Martí-Cruchaga P; Zozaya G; Blanco N; Ponz M; Chopitea A; Rodríguez J; Castañón E; Pardo F; Rotellar F
    BJS Open; 2024 Sep; 8(5):. PubMed ID: 39329454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing upfront surgery with neoadjuvant treatments in patients with resectable, borderline resectable or locally advanced pancreatic cancer: a systematic review and network meta-analysis of randomized clinical trials.
    He J; Lv N; Yang Z; Luo Y; Zhong W; Wu C
    Int J Surg; 2024 Jun; 110(6):3900-3909. PubMed ID: 38935819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The involvement of the hepatic artery is a risk factor for unresectability after neoadjuvant treatment in borderline pancreatic adenocarcinoma.
    Secanella L; Busquets J; Peláez N; Sorribas M; Laquente B; Ruiz-Osuna S; Fabregat J
    Surg Oncol; 2024 Feb; 52():102027. PubMed ID: 38113726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials.
    van Dam JL; Janssen QP; Besselink MG; Homs MYV; van Santvoort HC; van Tienhoven G; de Wilde RF; Wilmink JW; van Eijck CHJ; Groot Koerkamp B;
    Eur J Cancer; 2022 Jan; 160():140-149. PubMed ID: 34838371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained Carbohydrate Antigen 19-9 Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer Predicts Progression and Survival.
    Rose JB; Edwards AM; Rocha FG; Clark C; Alseidi AA; Biehl TR; Lin BS; Picozzi VJ; Helton WS
    Oncologist; 2020 Oct; 25(10):859-866. PubMed ID: 32277842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.
    Versteijne E; Vogel JA; Besselink MG; Busch ORC; Wilmink JW; Daams JG; van Eijck CHJ; Groot Koerkamp B; Rasch CRN; van Tienhoven G;
    Br J Surg; 2018 Jul; 105(8):946-958. PubMed ID: 29708592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of carbohydrate antigen 19-9 level and tumor size after neoadjuvant chemoradiation therapy may predict early recurrence of resectable pancreatic ductal adenocarcinoma.
    Terai T; Nagai M; Nakamura K; Kohara Y; Yasuda S; Matsuo Y; Doi S; Sakata T; Sho M
    Pancreatology; 2023 Dec; 23(8):970-977. PubMed ID: 37914628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.
    Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH
    Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer.
    Liu H; D'Alesio M; AlMasri S; Hammad A; Desilva A; Lebowitz S; Rieser C; Ashwat E; Hampton E; Khachfe H; Laffey M; Singhi A; Bahary N; Lee K; Zureikat A; Paniccia A
    HPB (Oxford); 2023 May; 25(5):521-532. PubMed ID: 36804826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reconsideration of the clinical impact of neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: A dual-institution collaborative clinical study.
    Yamada S; Hashimoto D; Yamamoto T; Yamaki S; Oshima K; Murotani K; Sekimoto M; Nakao A; Satoi S
    Pancreatology; 2024 Jun; 24(4):592-599. PubMed ID: 38548551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A striking elevation of CA19-9 after preoperative therapy negates prognostic benefit from radical surgery in resectable and borderline resectable pancreatic cancer.
    Akita H; Mukai Y; Kubo M; Takahashi H; Hasegawa S; Kitakaze M; Matsuura N; Masuike Y; Sugase T; Shinno N; Kanemura T; Hara H; Sueda T; Nishimura J; Yasui M; Omori T; Miyata H; Ohue M; Wada H
    Surgery; 2024 Oct; 176(4):1215-1221. PubMed ID: 39079828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
    Thanikachalam K; Damarla V; Seixas T; Dobrosotskaya I; Wollner I; Kwon D; Winters K; Raoufi M; Li J; Siddiqui F; Khan G
    Am J Clin Oncol; 2020 Jun; 43(6):435-441. PubMed ID: 32251119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative MDCT Assessment of Resectability in Borderline Resectable Pancreatic Cancer: Effect of Neoadjuvant Chemoradiation Therapy.
    Joo I; Lee JM; Lee ES; Ahn SJ; Lee DH; Kim SW; Ryu JK; Oh DY; Kim K; Lee KB; Jang JY
    AJR Am J Roentgenol; 2018 May; 210(5):1059-1065. PubMed ID: 29489408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749).
    Tachezy M; Gebauer F; Petersen C; Arnold D; Trepel M; Wegscheider K; Schafhausen P; Bockhorn M; Izbicki JR; Yekebas E
    BMC Cancer; 2014 Jun; 14():411. PubMed ID: 24906700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.